Cash and cash equivalents: Cash is the money readily available in the form of currency. Cash equivalents are the near-cash items, which are readily convertible into cash. Cash equivalents have a maturity period of three months, or less than 3 months. To compute: Monthly cash expenses for Year 3, Year 2 and Year 1.

Question

Cash to Monthly Cash Expenses Ratio Amicus Therapeutics, Inc., is a biopharmaceutical company that develops drugs for the treatment of various diseases, including Parkinson's disease. Amicus Therapeutics reported the following financial data (in thousands) for three recent years: For Years Ended December 31 Year 1 Year 3 Year 2 Cash and cash equivalents $69,485 $24,074 $43,640 Net cash flows from operations (100,139) (51,669) (45,794) a. Determine the monthly cash expenses for Year 3, Year 2, and Year 1 (in thousands). Round to one decimal place. Year 3: per month Year 2: per month per month Year 1: b. Determine the ratio of cash to monthly cash expenses for Year 3, Year 2, and Year 1 as of December 31. Round to one decimal place. months Year 3: months Year 2: months Year 1:

Answer 1

Question

Chapter 8, Problem 8.28EX

(a)

To determine

Cash and cash equivalents: Cash is the money readily available in the form of currency. Cash equivalents are the near-cash items, which are readily convertible into cash. Cash equivalents have a maturity period of three months, or less than 3 months.

To compute: Monthly cash expenses for Year 3, Year 2 and Year 1.

(b)

To determine

To compute: the ratio of cash to monthly cash expenses.

(c)

To determine

To comment: Ratio of cash to monthly operating expenses for Year 3, Year 2, and Year 1.

Expert Solution & Answer

Trending nowThis is a popular solution!

See solution

Check out sample textbook solution

Students have asked these similar questions

Cash to Monthly Cash Expenses Ratio Amicus Therapeutics, Inc., is a biopharmaceutical company that develops drugs for the treatment of various diseases, including Parkinson's disease. Amicus Therapeutics reported the following financial data (in thousands) for three recent years: For Years Ended December 31 Year 1 Year 3 Year 2 Cash and cash equivalents $69,485 $24,074 $43,640 Net cash flows from operations (100,139) (51,669) (45,794) a. Determine the monthly cash expenses for Year 3, Year 2, and Year 1 (in thousands). Round to one decimal place. Year 3: per month Year 2: per month per month Year 1: b. Determine the ratio of cash to monthly cash expenses for Year 3, Year 2, and Year 1 as of December 31. Round to one decimal place. months Year 3: months Year 2: months Year 1:

Cash to Monthly Cash Expenses Ratio Amicus Therapeutics, Inc., is a biopharmaceutical company that develops drugs for the treatment of various diseases, including Parkinson’s disease. Amicus Therapeutics reported the following financial data (in thousands) for three recent years: For Years Ended December 31 Year 3 Year 2 Year 1 Cash and cash equivalents $11,880 $19,170 $31,820 Net cash flows from operations (26,400) (32,400) (44,400) a. Determine the monthly cash expenses for Year 3, Year 2, and Year 1 (in thousands). Year 3: $fill in the blank 1 per month Year 2: $fill in the blank 2 per month Year 1: $fill in the blank 3 per month b. Determine the ratio of cash to monthly cash expenses for Year 3, Year 2, and Year 1 as of December 31. Round to one decimal place. Year 3: fill in the blank 4 months Year 2: fill in the blank 5 months Year 1: fill in the blank 6 months

Financial statement data for years ending December 31 for Newton Company follow: Line Item Description 20Y9 20Y8 Cash (end of year) $26,270 $23,260 Short-term investments (end of year) 8,290 9,500 Operating expenses 60,070 62,700 Depreciation expense 13,350 11,600 Determine the days’ cash on hand for 20Y8 and 20Y9. Assume 365 days in a year. Year Days’ Cash on Hand 20Y8: fill in the blank 1 of 2 days 20Y9: fill in the blank 2 of 2 days